Skip to main content
Apt Medical Inc. logo

Apt Medical Inc. — Investor Relations & Filings

Ticker · 688617 ISIN · CNE100004C45 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2024-03-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688617

About Apt Medical Inc.

https://www.aptmed.com/

Apt Medical Inc. is a specialized developer and manufacturer of advanced medical devices for minimally invasive vascular interventions. The company focuses on the fields of electrophysiology, interventional cardiology, and peripheral vascular procedures. Its product portfolio includes diagnostic and ablation catheters, steerable sheaths, guide wires, microcatheters, and balloon catheters designed for complex cardiovascular treatments. Apt Medical emphasizes research and development to provide high-precision tools for clinicians, aiming to improve procedural outcomes in the treatment of cardiac arrhythmias and vascular diseases. The company serves a global market, providing integrated solutions for interventional procedures through a commitment to technological innovation and quality manufacturing standards.

Recent filings

Filing Released Lang Actions
关于公司放弃优先购买权、与关联方共同投资暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen Huitai Medical Device Co., Ltd. regarding a transaction involving the waiver of preemptive rights and joint investment with related parties, constituting a related-party transaction. It includes extensive information about the transaction, the parties involved, shareholding structures before and after the transaction, financial data of related entities, legal and procedural compliance, and approvals from the board, supervisory committee, and independent directors. The document is not a financial report, earnings release, or management discussion but a formal disclosure of a related-party transaction and corporate governance matters related to it. It does not announce voting results or dividends, nor is it a merger or acquisition filing. The content fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about a related-party transaction and corporate governance compliance without being a full financial report or other specific filing type.
2024-03-24 Chinese
2023年年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Annual Special Report on the Deposit and Actual Use of Raised Funds" by Shenzhen Huitai Medical Device Co., Ltd. It details the company's fundraising activities, including the amount raised from an IPO, the management and use of the raised funds, specific projects funded, and cash management of idle raised funds. The document includes detailed financial figures related to the raised funds, their usage, and management policies. It is a comprehensive report focused on the use and management of capital raised through equity issuance, not a general annual report or earnings release. This type of document corresponds to a Capital/Financing Update, as it provides updates on fundraising and capital usage rather than full financial statements or earnings results. The document length is substantial (15,000 characters), and it contains detailed substantive financial data about fundraising and capital use, not just an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-03-24 Chinese
立信会计师事务所（特殊普通合伙）关于深圳惠泰医疗器械股份有限公司2023年度募集资金存放与实际使用情况专项报告的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "鉴证报告" (assurance report) on the "募集资金存放与实际使用情况专项报告" (special report on the deposit and actual use of raised funds) for the year 2023 by Shenzhen Huitai Medical Device Co., Ltd. It is issued by a certified public accounting firm (立信会计师事务所) and references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange. The content includes detailed financial data on the raised funds, their management, usage, and investment products related to idle raised funds. This is a standalone audit/assurance report focused on the use of raised capital, not a full annual or interim report. It is not a mere announcement or certification letter but contains substantive financial and compliance information. Therefore, it fits the category of an Audit Report / Information (AR).
2024-03-24 Chinese
立信会计师事务所（特殊普通合伙）关于深圳惠泰医疗器械股份有限公司2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' for the fiscal year 2023. It includes references to auditing standards, responsibilities of the company and auditors, and an audit opinion on the effectiveness of internal control over financial reporting. The document is issued by a certified public accounting firm with official certification details and signatures. The content is focused on the audit of internal controls rather than a full annual report or financial statements. The length is about 2513 characters, which is relatively short but contains substantive audit content, not just an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR) rather than an Annual Report (10-K) or Regulatory Filing (RNS).
2024-03-24 Chinese
关于董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee evaluating the performance and supervision of the accounting firm (立信会计师事务所) for the fiscal year 2023. It discusses the audit procedures, the audit firm's qualifications, the audit process, and the committee's oversight activities related to the 2023 annual audit. The document references the 2023 annual financial statements and audit reports but does not contain the financial statements themselves. It is a standalone report focused on audit oversight and the audit firm's performance, which fits the definition of an Audit Report / Information (AR). The document length is 2173 characters, which is relatively short but contains substantive content about audit supervision rather than just an announcement or certification. Therefore, it is classified as AR with high confidence. FY 2023
2024-03-24 Chinese
第二届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the second board of directors of Shenzhen Huitai Medical Devices Co., Ltd. It includes multiple agenda items such as approval of the 2023 annual report, financial reports, special reports, budget, work reports, remuneration plans, and other governance matters. The document repeatedly states that the detailed reports and documents are disclosed separately on the Shanghai Stock Exchange website, indicating this document itself is not the full reports but a summary of board meeting decisions. The document is a formal announcement of board meeting resolutions, which is characteristic of Board/Management Information filings. It is not the full annual report (10-K), audit report (AR), or any other detailed report but a board meeting resolution announcement. Therefore, the correct classification is Board/Management Information (MANG). The document length (4696 characters) and content support this classification with high confidence.
2024-03-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.